These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11792412)

  • 1. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K
    Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
    Sasaki K; Niitsu N
    Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
    Shah N; Cabanillas F; McIntyre B; Feng L; McLaughlin P; Rodriguez MA; Romaguera J; Younes A; Hagemeister FB; Kwak L; Fayad L
    Leuk Lymphoma; 2012 Jan; 53(1):50-6. PubMed ID: 21895545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K; Chizuka A
    Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
    Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
    Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
    Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
    Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.
    Molica S; Vitelli G; Levato D; Giannarelli D; Gandolfo GM
    Cancer; 2001 Aug; 92(4):713-9. PubMed ID: 11550139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
    Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
    Khalifa KA; Alkilani AA; Ismail H; Soliman MA
    J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma.
    Melnyk A; Rodriguez A; Pugh WC; Cabannillas F
    Blood; 1997 Jun; 89(12):4514-20. PubMed ID: 9192775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
    Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
    Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
    J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma.
    Mäenpää H; Ristamäki R; Virtamo J; Franssila K; Albanes D; Joensuu H
    Leuk Lymphoma; 2000 May; 37(5-6):585-92. PubMed ID: 11042519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
    Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum soluble CD44 in pediatric patients with acute leukemia.
    Takeuchi M; Tanizawa A; Fukumoto Y; Kikawa Y; Mayumi M
    J Pediatr Hematol Oncol; 1999; 21(5):384-8. PubMed ID: 10524451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
    Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Okabe-Kado J; Kasukabe T; Yamamoto-Yamaguchi Y; Umeda M; Honma Y
    Blood; 1999 Nov; 94(10):3541-50. PubMed ID: 10552965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CD44 in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Jalkanen S
    Leuk Lymphoma; 1999 May; 33(5-6):433-40. PubMed ID: 10342571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.